抗乙型肝炎病毒新药——恩替卡韦

A new antiviral drug against hepatitis B virus—entecavir

恩替卡韦(entecavir,ETV)是环戊基鸟苷类似物,作为一个新的抗HBV有效的药物,最近获得美国FDA上市的批准。恩替卡韦的临床试验项目是目前为止规模最大的慢性乙型肝炎试验,该试验首次直接比较了2种抗病毒药物,即ETV和拉米夫定(lamivudine,LVD),这些研究证实ETV具有较强的抑制HBV复制的作用,其安全性和LVD相似,耐药性很低。文中从药理作用、药代动力学、临床疗效和病毒变异等方面阐述。

Entecavir（ETV）, a cyclopentyl guanosine analogue, acquired the admission of FDA on sale as an new potent anti-HBV drug recently. The clinic trial project of ETV is so far the largest scale, which at the first directly compare two antiviral drugs-ETV and lamivudine（LVD）. The trial results demonstrate ETV is an potent drug against HBV, and similar to LVD in,safty, and superior to LVD in drug resistance. We deserible it from pharmacology, pharmacokinetic, clincial efficacy and viral mutation.